From PCOS to PMOS: A new name gives hope

A new name for a long-known condition has sparked hope among patients and researchers alike. The term “Polycystic Ovary Syndrome” (PCOS) is being replaced with “Polymetabolic Endocrine Ovarian Syndrome” (PMOS). This change, driven by patient advocates and medical experts, aims to better reflect the complexity of the condition and improve both research and treatment approaches. The shift began over a decade ago, when Dr. Helene Teede, an Australian endocrinologist, realized that the old name was misleading. For more than 14 years, she had been explaining to her patients that they did not have cysts in their ovaries, something that early physicians mistakenly identified as such. Instead, these were immature eggs, which were not always present in all patients. What was clear, however, was that PCOS was not just an ovarian issue, it was a systemic disorder affecting multiple body systems. Modern understanding reveals that the core features of the syndrome involve hormonal imbalances and metabolic disturbances. Patients often experience insulin resistance and elevated levels of androgens, such as testosterone. These factors contribute to irregular menstrual cycles, infertility, weight gain, and increased facial hair growth. Recent studies have also linked the condition to a higher risk of heart disease and type 2 diabetes, yet many healthcare providers overlook these connections. Dr. Teede argues that misclassifying the condition as an ovarian disorder limits meaningful research and appropriate treatment. She explains that current medical attention focuses primarily on gynecologists, while specialists in cardiology, diabetes care, and mental health remain underrepresented in the discussion. This narrow perspective, she says, leads to incomplete diagnosis and inadequate management of the condition’s broader implications. To address this, Dr. Teede and Dr. Andrea Dunaif initiated a process involving patients and experts from around the world. They organized online surveys and discussions with groups from six continents, ensuring that the renaming effort reflected both scientific accuracy and cultural sensitivity. The goal was not only to update terminology but also to reduce stigma and promote holistic care. After extensive deliberation, the group agreed that the name should be changed to PMOS, standing for “Polyendocrine Metabolic Ovarian Syndrome.” This new designation reflects the multifaceted nature of the condition, emphasizing its impact beyond the reproductive system. The decision was announced at the 28th European Conference on Endocrinology and published in The Lancet, a prestigious medical journal. Despite the symbolic significance of the name change, challenges remain. While PMOS offers a more accurate description, it does not automatically resolve all issues facing patients. Many still struggle with delayed diagnoses, limited access to comprehensive care, and societal misconceptions. The next step will likely involve further education for healthcare professionals and continued advocacy to ensure that the new name translates into tangible improvements in patient outcomes. For now, the focus remains on advancing research and improving clinical practices. With the new name in place, there is renewed optimism that the condition will finally receive the attention and resources it deserves.